1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prostate fibroblasts and prostate cancer associated fibroblasts exhibit different metabolic, matrix degradation and PD-L1 expression responses to hypoxia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fibroblasts are versatile cells that play a major role in wound healing by synthesizing and remodeling the extracellular matrix (ECM). In cancers, fibroblasts play an expanded role in tumor progression and dissemination, immunosuppression, and metabolic support of cancer cells. In prostate cancer (PCa), fibroblasts have been shown to induce growth and increase metastatic potential. To further understand differences in the functions of human PCa associated fibroblasts (PCAFs) compared to normal prostate fibroblasts (PFs), we investigated the metabolic profile and ECM degradation characteristics of PFs and PCAFs using a magnetic resonance imaging and spectroscopy compatible intact cell perfusion assay. To further understand how PFs and PCAFs respond to hypoxic tumor microenvironments that are often observed in PCa, we characterized the effects of hypoxia on PF and PCAF metabolism, invasion and PD-L1 expression. We found that under normoxia, PCAFs displayed decreased ECM degradation compared to PFs. Under hypoxia, ECM degradation by PFs increased, whereas PCAFs exhibited decreased ECM degradation. Under both normoxia and hypoxia, PCAFs and PFs showed significantly different metabolic profiles. PD-L1 expression was intrinsically higher in PCAFs compared to PFs. Under hypoxia, PD-L1 expression increased in PCAFs but not in PFs. Our data suggest that PCAFs may not directly induce ECM degradation to assist in tumor dissemination, but may instead create an immune suppressive tumor microenvironment that further increases under hypoxic conditions. Our data identify the intrinsic metabolic, ECM degradation and PD-L1 expression differences between PCAFs and PFs under normoxia and hypoxia that may provide novel targets in PCa treatment.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Cancer statistics, 2022

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation and Function of the PD-L1 Checkpoint

            Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.

              Adaptation of cancer cells to their microenvironment is an important driving force in the clonal selection that leads to invasive and metastatic disease. O2 concentrations are markedly reduced in many human cancers compared with normal tissue, and a major mechanism mediating adaptive responses to reduced O2 availability (hypoxia) is the regulation of transcription by hypoxia-inducible factor 1 (HIF-1). This review summarizes the current state of knowledge regarding the molecular mechanisms by which HIF-1 contributes to cancer progression, focusing on (1) clinical data associating increased HIF-1 levels with patient mortality; (2) preclinical data linking HIF-1 activity with tumor growth; (3) molecular data linking specific HIF-1 target gene products to critical aspects of cancer biology and (4) pharmacological data showing anticancer effects of HIF-1 inhibitors in mouse models of human cancer.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/1045033/overviewRole: Role: Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/1102442/overviewRole: Role:
                Role: Role:
                Role: Role:
                URI : https://loop.frontiersin.org/people/734660/overviewRole: Role:
                URI : https://loop.frontiersin.org/people/1025560/overviewRole: Role:
                URI : https://loop.frontiersin.org/people/85189/overviewRole: Role:
                URI : https://loop.frontiersin.org/people/211866/overviewRole: Role: Role: Role: Role:
                Journal
                Front Mol Biosci
                Front Mol Biosci
                Front. Mol. Biosci.
                Frontiers in Molecular Biosciences
                Frontiers Media S.A.
                2296-889X
                22 March 2024
                2024
                : 11
                : 1354076
                Affiliations
                [1] 1 Division of Cancer Imaging Research , The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , Baltimore, MD, United States
                [2] 2 Instituto de Investigaciones Biomédicas Sols-Morreale , CSIC , Madrid, Spain
                [3] 3 Sidney Kimmel Comprehensive Cancer Center , The Johns Hopkins University School of Medicine , Baltimore, MD, United States
                [4] 4 Radiation Oncology and Molecular Radiation Sciences , The Johns Hopkins University School of Medicine , Baltimore, MD, United States
                Author notes

                Edited by: Zhou Xunian, MD Anderson Cancer Center, United States

                Reviewed by: Wanheng Zhang, Baylor College of Medicine, United States

                Meidan Wang, University of Freiburg, Germany

                Bingrui Li, University of Texas MD Anderson Cancer Center, United States

                *Correspondence: Zaver M. Bhujwalla, zbhujwa1@ 123456jhmi.edu
                Article
                1354076
                10.3389/fmolb.2024.1354076
                10995317
                86c07408-f53f-4484-93bd-8f24fcebdb94
                Copyright © 2024 Pacheco-Torres, Sharma, Mironchik, Wildes, Brennen, Artemov, Krishnamachary and Bhujwalla.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 11 December 2023
                : 06 February 2024
                Funding
                Funded by: National Institute for Health and Care Research , doi 10.13039/501100000272;
                Award ID: R35 CA209960 R01 CA82337 P41 EB024495 R01CA255259
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by NIH R35 CA209960, R01 CA82337, P41 EB024495 and P30 CA006973. JP-T was supported by Fundación Martín-Escudero and Marie Skłodowska-Curie Individual Fellowships. WB was supported by the National Cancer Institute (R01CA255259).
                Categories
                Molecular Biosciences
                Original Research
                Custom metadata
                Molecular Diagnostics and Therapeutics

                fibroblast,hypoxia,metabolism,prostate cancer,cancer associated fibroblast,pd-l1

                Comments

                Comment on this article